Semaglutide

Semaglutide is a 31-amino-acid synthetic GLP-1 receptor agonist developed by Novo Nordisk, marketed as Ozempic for type 2 diabetes, Wegovy for chronic weight management, and Rybelsus as the first oral GLP-1 receptor agonist. It received initial FDA approval in 2017 (Ozempic) and 2021 (Wegovy). Research-grade semaglutide is sold by third-party laboratories for laboratory use only — that material is not the FDA-approved prescription product and carries no pharmacy-grade quality controls.

What is semaglutide and how does it work?

Semaglutide activates the GLP-1 receptor to increase glucose-dependent insulin secretion, slow gastric emptying, suppress appetite via central pathways, and reduce hepatic glucose production. The molecule is modified from native GLP-1 with two amino acid substitutions and a C18 fatty diacid side chain that binds serum albumin, extending half-life to approximately 7 days and enabling once-weekly subcutaneous dosing. Rybelsus uses an oral absorption enhancer (SNAC) to achieve bioavailability through the gastric mucosa.

Evidence level: human RCT (multiple Phase 3 trials in STEP, SUSTAIN, and PIONEER programs)

What does the Phase 3 evidence show for semaglutide?

In STEP 1 (n=1,961), semaglutide produced an average weight loss of 14.9% at the 2.4 mg dose over 68 weeks in adults with obesity without type 2 diabetes, versus 2.4% for placebo. In type 2 diabetes (SUSTAIN program), semaglutide reduced HbA1c by up to 1.8 percentage points and demonstrated cardiovascular outcome benefit in SUSTAIN-6. The SELECT trial later established cardiovascular event reduction in obesity without diabetes — a first-in-class result.

Source: Once-Weekly Semaglutide in Adults with Overweight or Obesity, Wilding J.P.H. et al., N Engl J Med, 2021 · Evidence level: human RCT (Phase 3, multiple programs)

How does semaglutide compare to tirzepatide and retatrutide?

Semaglutide is the founding compound of the modern GLP-1 weight-loss class, but produces lower percent weight loss than the dual and triple agonists that followed it. Tirzepatide's SURMOUNT-1 result (22.5% at 72 weeks) exceeded semaglutide's STEP 1 result (14.9% at 68 weeks) A direct head-to-head Phase 3b trial, SURMOUNT-5 (n=751), settled the comparison in 2025: tirzepatide produced 20.2% average weight loss at 72 weeks versus 13.7% with semaglutide 2.4 mg. in matched populations, and SURPASS-2 demonstrated tirzepatide superiority head-to-head in type 2 diabetes. Retatrutide's Phase 3 readouts are exceeding both. Full cross-compound comparison is in our comparing semaglutide and tirzepatide guide.

Source: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity, Aronne L.J. et al. (SURMOUNT-5 Trial Investigators), N Engl J Med, 2025

What are the documented side effects of semaglutide?

The most common semaglutide side effects in STEP 1 were gastrointestinal — nausea (44%), diarrhea (32%), vomiting (25%), and constipation (24%) — typically mild-to-moderate and concentrated in the dose-escalation phase. Less common but clinically relevant signals include rare pancreatitis cases, gallbladder events, and reported "Ozempic face" / "Ozempic butt" cosmetic changes attributable to rapid fat loss. Discontinuation rates due to adverse events were 7.0% on semaglutide versus 3.1% on placebo. Evidence level: Human RCT (Phase 3). Cross-compound side effect comparison is in peptide side effects by compound and route.

Source: Once-Weekly Semaglutide in Adults with Overweight or Obesity, Wilding J.P.H. et al., N Engl J Med, 2021

What is the regulatory status of semaglutide?

Semaglutide is FDA-approved as Ozempic (type 2 diabetes, 2017), Rybelsus (oral, 2019), and Wegovy (chronic weight management, 2021), with EMA approval following for all three. It is available by prescription through licensed pharmacies. Research-grade semaglutide sold by third-party laboratories is not the FDA-approved prescription product. In December 2025 the FDA also approved an oral semaglutide 25 mg tablet (Wegovy pill) for chronic weight management — the first oral GLP-1 approved for that indication. The compounded-semaglutide era is over: the FDA declared the semaglutide shortage resolved on February 21, 2025, and its enforcement-discretion window for compounders closed on April 22, 2025 (503A pharmacies) and May 22, 2025 (503B outsourcing facilities). On April 30, 2026 the FDA went further, proposing to exclude semaglutide (along with tirzepatide and liraglutide) from the 503B bulks list after finding no clinical need for outsourcing facilities to compound them — a proposal still pending as of August 2026. For athletes: semaglutide is not on the WADA Prohibited List — it is tracked under WADA's 2026 Monitoring Program to detect patterns of misuse, which is not a ban. For prescription access pathways including telehealth options, see can you get semaglutide without a prescription.

Sources: Novo Nordisk announcement — FDA approval of Wegovy® pill (oral semaglutide 25 mg) for weight management, Novo Nordisk, via novonordisk.com (company announcement); FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, FDA, via fda.gov (Drug Alerts and Statements); FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List, FDA, via fda.gov (Press Announcements); WADA 2026 Monitoring Program — GLP-1 receptor agonist markers (semaglutide, tirzepatide) tracked; not prohibited, WADA (reported by EMJ Reviews), via EMJ Reviews (secondary; WADA primary PDF pending)

Why does semaglutide vendor verification matter even though it's FDA-approved?

Because FDA approval applies to Novo Nordisk's pharmacy-distributed Ozempic, Wegovy, and Rybelsus — not to research-grade semaglutide sold by third-party labs. Research-grade semaglutide is a separate supply chain with its own quality risks: wider purity variance, occasional underdosing, and inconsistent endotoxin control. Independent HPLC purity testing and mass spectrometry identity confirmation (expected MW 4,113.6 Da) are the only meaningful purity signals a research-grade vendor can provide. Learn how to interpret these in our how-to-test-peptides hub.

How does Peptigrity verify semaglutide vendors?

Peptigrity collects independent third-party Certificates of Analysis for semaglutide from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. The lab test table above this section shows the full cross-shop dataset, sortable by date, purity, and labeled-vs-tested quantity. Tests come from named labs including Freedom Diagnostics, Janoshik Analytical, Chromate, and Vanguard Laboratory. Methodology detail is in how we calculate trust scores.

Frequently asked questions

How can I verify a semaglutide vendor is selling real product?

The only reliable purity signal is an independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay. Peptigrity publishes independent semaglutide test results from independent labs in the table above. For COA interpretation, see red flags in peptide certificates of analysis and the compound-specific where to buy semaglutide guide.

Can I get semaglutide without a prescription?

Research-grade semaglutide is legally sold as a research chemical without prescription in most jurisdictions, but is not approved for human consumption. The FDA-approved versions (Ozempic, Wegovy, Rybelsus) require a prescription, which can be obtained through traditional medical care or telehealth platforms. Full pathway breakdown is in can you get semaglutide without a prescription.

Can I get semaglutide from a compounding pharmacy?

Compounding pharmacy access to semaglutide depends on FDA shortage status and 503A/503B regulations, both of which have shifted during 2024–2025. Generally no — that era ended in 2025. Mass compounding was lawful only while semaglutide was on the FDA shortage list. The FDA declared the shortage resolved on February 21, 2025, and its enforcement-discretion window closed on April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B outsourcing facilities. In April 2026 the FDA additionally proposed excluding semaglutide from the 503B bulks list, which would close the main remaining route permanently. For the full sequence of events, see the FDA peptide regulation 2025–2026 timeline. Track current status in FDA peptide regulation 2025–2026: the complete timeline.

Sources: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, FDA, via fda.gov (Drug Alerts and Statements); FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List, FDA, via fda.gov (Press Announcements)

Why does research-grade semaglutide cost less than Ozempic or Wegovy?

Research-grade semaglutide is manufactured without the pharmaceutical-grade overhead (FDA inspections, full GMP compliance, branded packaging, distribution markups) that prices the prescription products. It also carries no regulatory protection or quality guarantee. Current research-grade pricing is broken down in how much do peptides cost.

Does Peptigrity recommend a semaglutide dose?

No. Peptigrity is an independent review platform, not a medical authority. The doses studied in STEP and SUSTAIN (0.25 mg through 2.4 mg weekly, with mandatory titration) were administered under clinical supervision. Anyone considering semaglutide should consult a licensed physician about the prescription product.

How does semaglutide compare to tirzepatide for weight loss?

Tirzepatide produces larger percent weight loss than semaglutide — confirmed directly in the SURMOUNT-5 head-to-head trial (n=751), where tirzepatide averaged 20.2% weight loss at 72 weeks versus 13.7% for semaglutide 2.4 mg. The single-drug Phase 3 programs told the same story: 22.5% in SURMOUNT-1 (72 weeks) versus 14.9% in STEP 1 (68 weeks). Full comparison in our comparing semaglutide and tirzepatide guide.

Sources: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity, Aronne L.J. et al. (SURMOUNT-5 Trial Investigators), N Engl J Med, 2025; Tirzepatide Once Weekly for the Treatment of Obesity, Jastreboff A.M. et al., N Engl J Med, 2022; Once-Weekly Semaglutide in Adults with Overweight or Obesity, Wilding J.P.H. et al., N Engl J Med, 2021

This section is for educational and informational purposes only and does not constitute medical advice. Research-grade semaglutide sold for laboratory use is not the FDA-approved prescription product (Ozempic, Wegovy, Rybelsus). Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.